185 related articles for article (PubMed ID: 30952061)
21. Synthesis of disaccharide nucleoside analogues as potential poly(ADP-ribose) polymerase-1 inhibitors.
Zheng M; Mex M; Götz KH; Marx A
Org Biomol Chem; 2018 Nov; 16(46):8904-8907. PubMed ID: 30203829
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis, biological evaluation of novel piperidine-based derivatives as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors.
Lin C; Liu C; Hu P; Zou Z; Sun G
Bioorg Chem; 2024 Jul; 148():107455. PubMed ID: 38772289
[TBL] [Abstract][Full Text] [Related]
23. New Quinoxaline-Based Derivatives as PARP-1 Inhibitors: Design, Synthesis, Antiproliferative, and Computational Studies.
Syam YM; Anwar MM; Abd El-Karim SS; Elokely KM; Abdelwahed SH
Molecules; 2022 Aug; 27(15):. PubMed ID: 35956876
[TBL] [Abstract][Full Text] [Related]
24. Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1).
Zhang Z; Chang X; Zhang C; Zeng S; Liang M; Ma Z; Wang Z; Huang W; Shen Z
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1606-1615. PubMed ID: 32779949
[TBL] [Abstract][Full Text] [Related]
25. Discovery of Novel Apigenin-Piperazine Hybrids as Potent and Selective Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors for the Treatment of Cancer.
Long H; Hu X; Wang B; Wang Q; Wang R; Liu S; Xiong F; Jiang Z; Zhang XQ; Ye WC; Wang H
J Med Chem; 2021 Aug; 64(16):12089-12108. PubMed ID: 34404206
[TBL] [Abstract][Full Text] [Related]
26. Design of Selective PARP-1 Inhibitors and Antitumor Studies.
Zhang Y; Li X; Liu F; Bai X; Liu X; Sun H; Gao C; Lin Y; Xing P; Zhu J; Liu R; Wang Z; Dai J; Shi D
J Med Chem; 2024 Jun; 67(11):8877-8901. PubMed ID: 38776379
[TBL] [Abstract][Full Text] [Related]
27. Olaparib-Based Photoaffinity Probes for PARP-1 Detection in Living Cells.
Voorneveld J; Florea BI; Bakkum T; Mendowicz RJ; van der Veer MS; Gagestein B; van Kasteren SI; van der Stelt M; Overkleeft HS; Filippov DV
Chembiochem; 2020 Sep; 21(17):2431-2434. PubMed ID: 32282108
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis and biological evaluation of erythrina derivatives bearing a 1,2,3-triazole moiety as PARP-1 inhibitors.
Li S; Li XY; Zhang TJ; Zhu J; Xue WH; Qian XH; Meng FH
Bioorg Chem; 2020 Mar; 96():103575. PubMed ID: 31962202
[TBL] [Abstract][Full Text] [Related]
29. Novel tricyclic poly (ADP-ribose) polymerase-1/2 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis and biological evaluation.
Li H; Hu Y; Wang X; He G; Xu Y; Zhu Q
Bioorg Med Chem; 2016 Oct; 24(19):4731-4740. PubMed ID: 27561983
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis and biological evaluation of pyridazino[3,4,5-de]quinazolin-3(2H)-one as a new class of PARP-1 inhibitors.
Wang J; Tan H; Sun Q; Ge Z; Wang X; Wang Y; Li R
Bioorg Med Chem Lett; 2015 Jun; 25(11):2340-4. PubMed ID: 25899312
[TBL] [Abstract][Full Text] [Related]
31. Structure based pharmacophore study to identify possible natural selective PARP-1 trapper as anti-cancer agent.
Kumar C; P T V L; Arunachalam A
Comput Biol Chem; 2019 Jun; 80():314-323. PubMed ID: 31078910
[TBL] [Abstract][Full Text] [Related]
32. In silico investigation of PARP-1 catalytic domains in holo and apo states for the design of high-affinity PARP-1 inhibitors.
Salmas RE; Unlu A; Yurtsever M; Noskov SY; Durdagi S
J Enzyme Inhib Med Chem; 2016; 31(1):112-20. PubMed ID: 26083304
[TBL] [Abstract][Full Text] [Related]
33. Contrasting sirtuin and poly(ADP-ribose)polymerase activities of selected 2,4,6-trisubstituted benzimidazoles.
Yeong KY; Tan SC; Mai CW; Leong CO; Chung FF; Lee YK; Chee CF; Abdul Rahman N
Chem Biol Drug Des; 2018 Jan; 91(1):213-219. PubMed ID: 28719017
[TBL] [Abstract][Full Text] [Related]
34. 1-Oxo-3,4-dihydroisoquinoline-4-carboxamides as novel druglike inhibitors of poly(ADP-ribose) polymerase (PARP) with favourable ADME characteristics.
Safrygin A; Zhmurov P; Dar'in D; Silonov S; Kasatkina M; Zonis Y; Gureev M; Krasavin M
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1968-1983. PubMed ID: 34482781
[TBL] [Abstract][Full Text] [Related]
35. Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking and Biological Evaluation for Identification of Potential Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors.
Zhou Y; Tang S; Chen T; Niu MM
Molecules; 2019 Nov; 24(23):. PubMed ID: 31766720
[TBL] [Abstract][Full Text] [Related]
36. [Design, synthesis and biological evaluation of novel 3-(2-oxo-2-substituted acetamido)benzamides as PARP-1 inhibitors].
Yin YW; Ji M; Cao R; Chen XG; Xu BL
Yao Xue Xue Bao; 2015 Jun; 50(6):738-45. PubMed ID: 26521446
[TBL] [Abstract][Full Text] [Related]
37. Development of erythrina-based PARP-1/FTase dual-target inhibitors against lung cancer epithelial-mesenchymal transition (EMT) in vivo and in vitro.
Yu L; Wang YD; Yan ZW; Zhang LY; Li S
Bioorg Chem; 2024 Jul; 148():107480. PubMed ID: 38772291
[TBL] [Abstract][Full Text] [Related]
38. Examination of Diazaspiro Cores as Piperazine Bioisosteres in the Olaparib Framework Shows Reduced DNA Damage and Cytotoxicity.
Reilly SW; Puentes LN; Wilson K; Hsieh CJ; Weng CC; Makvandi M; Mach RH
J Med Chem; 2018 Jun; 61(12):5367-5379. PubMed ID: 29856625
[TBL] [Abstract][Full Text] [Related]
39. Design of potential anti-tumor PARP-1 inhibitors by QSAR and molecular modeling studies.
Abbasi-Radmoghaddam Z; Riahi S; Gharaghani S; Mohammadi-Khanaposhtanai M
Mol Divers; 2021 Feb; 25(1):263-277. PubMed ID: 32140890
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis and evaluation of phthalazinone thiohydantoin-based derivative as potent PARP-1 inhibitors.
Zhong Y; Meng Y; Xu X; Zhao L; Li Z; You Q; Bian J
Bioorg Chem; 2019 Oct; 91():103181. PubMed ID: 31404795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
